News
![Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc
![Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc
![Form 8.3 - The Vanguard Group, Inc.: HomeServe plc](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
![Xcel Energy Third Quarter 2022 Earnings Report: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24841/Xcel_Energy.JPG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaFlCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b533b42f5e5d3878ccf0fff14014a4ca8c3f814b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xcel_EnergyJPG.png?locale=us)
Xcel Energy Third Quarter 2022 Earnings Report
Xcel Energy Inc. (NASDAQ: XEL) today reported 2022 third quarter GAAP and ongoing earnings of $649 million, or $1.18 per share, compared with $609 million, or $1.13 per share in the same period in
ExxonMobil to Release Third Quarter 2022 Financial Results
Exxon Mobil Corporation will release third quarter 2022 financial results on Friday, October 28, 2022. A press release will be issued via Business Wire and available at 5:30 a.m. CT at www.exxonmob
![ContourGlobal plc](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
ContourGlobal plc
![Ermenegildo Zegna Group Reports Strong Revenue Growth in Third Quarter of 2022: https://mms.businesswire.com/media/20220405006206/en/1412232/5/Gruppo_Zegna.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK05EV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--69c14c69a5c345ae88fcf54082295dbcc5563e39/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Gruppo_Zegna.jpg?locale=us)
Ermenegildo Zegna Group Reports Strong Revenue Growth in Third Quarter of 2022
Ermenegildo Zegna N.V. (NYSE:ZGN) (“Zegna Group,” “the Group,” or “the Company”), owner of the Zegna and Thom Browne brands, today announced unaudited revenues of €357 million for the Third Quarter
![Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc
![Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc
![Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc
![Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
![Form 8.3 - The Vanguard Group, Inc.: Biffa plc](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Form 8.3 - The Vanguard Group, Inc.: Biffa plc
![Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
![Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=us)
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung
![Rights and Issues Investment Trust PLC: Net Asset Value(s)](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
![Chelverton UK Dividend Trust plc: Net Asset Value(s)](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
![Ørsted enters into agreement with Equinor on Norwegian gas for Denmark](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Ørsted enters into agreement with Equinor on Norwegian gas for Denmark
![Ørsted to present results for the first nine month of 2022 on 3 November](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Ørsted to present results for the first nine month of 2022 on 3 November
![Claro Brasil to Extend 4G and 5G-Ready Mobile Services Across Amazon Region with SES’s O3b mPOWER: https://mms.businesswire.com/media/20191129005253/en/290384/5/SES_Logo_BL_M.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHRZRkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--47420c82142be2d536d2fc244215ced782ecd26b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/SES_Logo_BL_M.jpg?locale=us)
Claro Brasil to Extend 4G and 5G-Ready Mobile Services Across Amazon Region with SES’s O3b mPOWER
With unprecedented demand for high-powered mobile connectivity in the most isolated communities of the Amazon, SES today announced it has signed a multiyear capacity renewal with Claro Brasil
![EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
![Superdry plc: DSH-Director/PDMR Shareholding*](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Superdry plc: DSH-Director/PDMR Shareholding*
![EQS-News: Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EQS-News: Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory
![Eurofins Celebrates 35 Years of Testing for Life and 25 Years as Best Performing Share Listed in Europe: https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNhTUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39aa1a81526ac2a70cd04ea71d1ab318c23b607c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/EUROFINS_.jpg?locale=us)
Eurofins Celebrates 35 Years of Testing for Life and 25 Years as Best Performing Share Listed in Europe
October marks the 35th anniversary of Eurofins (Paris:ERF). Today, the global leader in bio-analysis with 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins’ growth has